Exploring a new target for treating bone metastasis in cancer patients
Study of a new driver and therapeutic vulnerability of bone metastasis
This study is looking at a protein called ACBP to see how it affects the spread of cancer to bones, and it hopes to find new ways to treat patients with bone metastasis by changing how this protein works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11201506 on NIH RePORTER |
What this research studies
This research investigates a novel driver of bone metastasis, focusing on the acyl-CoA binding protein (ACBP) and its role in cancer progression. By utilizing advanced CRISPR technology, the study aims to understand how manipulating ACBP can affect cancer cell behavior and potentially improve treatment outcomes. The approach includes both genetic screening and metabolic analysis to uncover the mechanisms behind ACBP's influence on bone metastasis. Patients may benefit from new therapeutic strategies that target this protein, leading to more effective treatments for bone metastasis.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with bone metastasis, particularly those with breast cancer or other cancers that commonly spread to bone.
Not a fit: Patients without bone metastasis or those with early-stage cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that significantly improve the management of bone metastasis in cancer patients.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach could be effective, although the specific focus on ACBP is novel.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Ma, Li — University of Tx Md Anderson Can Ctr
- Study coordinator: Ma, Li
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.